Merck KGaA agreed to acquire Bio-Techne in a deal valued at about $11.3 billion, expanding the acquirer’s life science tools, diagnostics, and multiomics offerings. The all-cash offer is $73 per Bio-Techne share, a 36% premium to the one-month volume-weighted average trading price and 24% above the prior close. The transaction adds Bio-Techne’s ProteinSimple automated protein analysis system, RNAscope multiplex RNA in situ hybridization technology, and its recombinant protein and immunoassay portfolio. Merck KGaA also expects Bio-Techne’s position in cell therapy tools and workflows to strengthen its platform approach across discovery, testing, and manufacturing. Merck KGaA said the acquisition is expected to close by late 2026 or early 2027 and anticipates cost synergies of roughly €140 million by year three, funding the purchase through a combination of existing cash and new debt. For Bio-Techne and downstream customers, the deal signals consolidation in high-growth life science instrumentation and reagents—areas that benefit from increasing adoption of multiomics and spatial biology in drug development.